NCT03115736View on ClinicalTrials.gov

TAF for HIV-HBV With Renal Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

December 5, 2019

Study Completion Date

December 5, 2019

Conditions
HIV and Hepatitis B Coinfection
Interventions
DRUG

Tenofovir Alafenamide

Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen

Trial Locations (8)

1004

Cabinet médical Chave-Crottaz-Roggerto, Lausanne

1011

Centre hospitalier universitaire vaudois (CHUV), Lausanne

1211

Department of Infectious Diseases, Hôpitaux Universitaires de Genève, Geneva

3010

Inselspital, Bern

4031

Klinik für Infektiologie und Spitalhygiene, Universitätspital Basel, Basel

6903

Ospedale Regionale di Lugano, Lugano

8091

Klinik für Infektionskrankheiten & Spitalhygiene, Universitätsspital Zürich, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03115736 - TAF for HIV-HBV With Renal Dysfunction | Biotech Hunter | Biotech Hunter